DMKN and melanoma: Moreover, the paper explores potential druggable targets for melanoma patients, including ERK5, CD73, ALDH1A1, PLA1A, and DMKN, which hold promise in addressing diagnostic hurdles and guiding personalized therapeutic decisions.